Page 74 - CIBERDEM-2015-eng

Research groups
Diabetes and Metabolism Research Group
Programme: P1
Lead Researcher: Simó Canonge, Rafael
Group members
STAFF MEMBERS: Bogdanov, Patricia Mónica | Corraliza Márquez, Lidia | García Ramírez, Marta | Ramos Pérez, Lorena.
ASSOCIATED MEMBERS: Ciudín, Andreea | Enquix Elena, Natalia | Hernández Pascual, Cristina | Lecube Torello, Albert | Martínez Selva, David | Mesa Manteca, Jorge | Sáez López, Cristina | Sola Adell, Cristina | Villena Delgado, Josep Antoni.
Main lines of research
1. Physiopathology of diabetic retinopathy : The main aim of this line of research is to identify new targets for the treatment of diabetic retinopathy (DR). In this regard it should be noted that we are co- ordinating the first clinical trial aimed at testing the effectiveness and safety of neuroprotective agents for the treatment of DR (EudraCT -2012-001200- 38). This project has been funded by EC (EURO- CONDOR-HEALTH-2011- FP7-278040). In addition, is also noteworthy that we are partners of the pro- ject “Early Prevention of Diabetes Complications in people with hyperglycaemia in Europe” (e-PREDICE. FP7-279074) in which we are the responsible for measuring the biomarkers of DR.
2. Insulin resistance and obesity: new pathogenic candidates and the study of co-morbidities. The main objective is to investigate the pathogenic
mechanisms of obesity and its co-morbidities and to find out new therapeutic targets. As a result of our recent findings we are giving priority to the role of sex hormone binding globulin (SHBG) and mito- chondrial dysfunction in the pathogenesis of obesi- ty, insulin-resistance and type 2 diabetes.
3. Endothelial dysfunction, dyslipideamia and car- diovascular disease in type 2 diabetes.: We are exploring non-classic cardiovascular risk factors. In this setting is worth mentioning our key participation in the project “Preventing cardiovascular ischemic events and arresting their consequences in type 2 diabetic population: a multidisciplinary clinical and experimental approach”, which has been funded by the Ministerio de Economía y Competitividad.
4. Diabetes as a metabolic accelerator of Alzheim- er’s disease.: In this regard it should be noted that
74 I Annual report 2015 I CIBERDEM